Immunocore

Immunocore

Primary Menu

  • About us
    • Management Team
    • Board of Directors
    • Partners
  • Our science
    • Pipeline
    • Publications
    • Scientific Advisory Board
  • Our therapy areas
    • Oncology
    • Infectious Diseases
    • Autoimmune and Inflammation Diseases
  • For patients
  • News
  • Contact us
  • Careers

Primary Menu

  • About us
  • Our science
  • Our therapy areas
  • For patients
  • News
  • Contact us
  • Careers
  1. Home
  2. /
  3. News

News

  • 8 June 2016

    Immunocore’s ImmTAV shown to redirect the immune system to kill HIV-infected cells from patients treated with antiretroviral therapy
  • 6 June 2016

    Immunocore Presents Positive IMCgp100 Phase I Data at the 2016 ASCO Annual Meeting
  • 30 March 2016

    Immunocore’s IMCgp100 Starts Phase I Trial for the Treatment of Uveal Melanoma
  • 25 January 2016

    Immunocore’s IMCgp100 Granted Orphan Drug Designation by US FDA for the Treatment of Uveal Melanoma
  • 20 January 2016

    Immunocore Starts Clinical Trial with IMCgp100 in Combination with MedImmune Immunotherapies Durvalumab and Tremelimumab
  • 6 January 2016

    Immunocore and GlaxoSmithKline Select First ImmTAC Clinical Candidate in Discovery Collaboration
  • 17 December 2015

    Immunocore expands its senior management team and opens US Office
  • 3 December 2015

    Immunocore wins Biotech of the Year at the SCRIP Awards 2015
  • 9 September 2015

    Immunocore’s IMCgp100 Accepted for Adaptive Pathway Pilot Programme
  • 7 September 2015

    Immunocore Ranked No 1 South East Company in the Annual Sunday Times Hiscox Tech Track 100
  • ← Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6 (current)
  • 7
  • 8
  • 9
  • 10
  • 11
  • Next →

Sign up to receive news email alerts

News archive
  • Show all
  • 2021 (1)
  • 2020 (8)
  • 2019 (13)
  • 2018 (10)
  • 2017 (13)
  • 2016 (11)
  • 2015 (20)
  • 2014 (6)
  • 2013 (11)
  • 2012 (3)
  • 2011 (1)
  • 2010 (4)
  • 2009 (1)
  • 2008 (1)

Immunocore

Immunocore
  • About us
  • Our science
  • Our therapy areas
  • For patients
  • News
  • Contact us
  • Privacy and Social Media Guidelines
  • Cookies
  • Payments and Disclosures
  • Clinical trials

©2021 Immunocore, Ltd. All rights reserved. ImmTAC, ImmTAV, ImmTAB, ImmTAAI and ImmTAX are all registered trademarks of Immunocore, Ltd